443 related articles for article (PubMed ID: 28577620)
1. Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice.
Kazi DS; Penko JM; Bibbins-Domingo K
Med Clin North Am; 2017 Jul; 101(4):689-699. PubMed ID: 28577620
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease risk assessment and prevention: current guidelines and limitations.
Alagona P; Ahmad TA
Med Clin North Am; 2015 Jul; 99(4):711-31. PubMed ID: 26042878
[TBL] [Abstract][Full Text] [Related]
5. Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence.
Gurwitz JH; Go AS; Fortmann SP
JAMA; 2016 Nov; 316(19):1971-1972. PubMed ID: 27838724
[No Abstract] [Full Text] [Related]
6. Intensive statin therapy for Indians: Part-I. Benefits.
Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
[TBL] [Abstract][Full Text] [Related]
7. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease.
Thanassoulis G; Williams K; Altobelli KK; Pencina MJ; Cannon CP; Sniderman AD
Circulation; 2016 Apr; 133(16):1574-81. PubMed ID: 26945047
[TBL] [Abstract][Full Text] [Related]
8. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.
Jarmul J; Pletcher MJ; Hassmiller Lich K; Wheeler SB; Weinberger M; Avery CL; Jonas DE; Earnshaw S; Pignone M
Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004171. PubMed ID: 29650716
[TBL] [Abstract][Full Text] [Related]
10. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study.
Ramos R; Comas-Cufí M; Martí-Lluch R; Balló E; Ponjoan A; Alves-Cabratosa L; Blanch J; Marrugat J; Elosua R; Grau M; Elosua-Bayes M; García-Ortiz L; Garcia-Gil M
BMJ; 2018 Sep; 362():k3359. PubMed ID: 30185425
[TBL] [Abstract][Full Text] [Related]
11. Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial.
Bonnet F; Bénard A; Poulizac P; Afonso M; Maillard A; Salvo F; Berdaï D; Salles N; Rousselot N; Marchi S; Hayes N; Joseph JP
Trials; 2020 Apr; 21(1):342. PubMed ID: 32307005
[TBL] [Abstract][Full Text] [Related]
12. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence.
Ali R; Alexander KP
Am J Geriatr Pharmacother; 2007 Mar; 5(1):52-63. PubMed ID: 17608248
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
15. Primary Prevention With Statins in the Elderly.
Mortensen MB; Falk E
J Am Coll Cardiol; 2018 Jan; 71(1):85-94. PubMed ID: 29301631
[TBL] [Abstract][Full Text] [Related]
16. Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease.
Djulbegovic B; Tsalatsanis A; Hozo I
J Eval Clin Pract; 2017 Apr; 23(2):241-250. PubMed ID: 26555150
[TBL] [Abstract][Full Text] [Related]
17. Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia.
Bosomworth NJ
J Am Board Fam Med; 2016 Nov; 29(6):727-740. PubMed ID: 28076256
[TBL] [Abstract][Full Text] [Related]
18. Statins and the elderly: recent evidence and current indications.
Schiattarella GG; Perrino C; Magliulo F; Ilardi F; Serino F; Trimarco V; Izzo R; Amato B; Terranova C; Cardin F; Militello C; Leosco D; Trimarco B; Esposito G
Aging Clin Exp Res; 2012 Jun; 24(3 Suppl):47-55. PubMed ID: 23160507
[TBL] [Abstract][Full Text] [Related]
19. Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis.
Ueda P; Lung TW; Clarke P; Danaei G
Br J Gen Pract; 2017 Sep; 67(662):e598-e608. PubMed ID: 28760741
[TBL] [Abstract][Full Text] [Related]
20. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.
Yebyo HG; Aschmann HE; Puhan MA
Ann Intern Med; 2019 Jan; 170(1):1-10. PubMed ID: 30508425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
